Buspirone transdermal - Bristol-Myers Squibb/Elan
Alternative Names: BuSpar PatchLatest Information Update: 05 Nov 2023
At a glance
- Originator Bristol-Myers Squibb
- Class Antidepressants; Anxiolytics; Pyrimidines; Small molecules; Spiro compounds
- Mechanism of Action 5-HT1A serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anxiety disorders; Attention-deficit hyperactivity disorder; Major depressive disorder
Most Recent Events
- 18 Jun 2001 Discontinued-III for Anxiety disorders in USA (Transdermal)
- 18 Jun 2001 Discontinued-III for Anxiety disorders in Western Europe (Transdermal)
- 18 Jun 2001 Discontinued-III for Attention-deficit hyperactivity disorder in USA (Transdermal)